|
NEUROPSYCHIATRY RESEARCH LINKS:
For More Information:
Fifteen Medical Park
Suite 301
Columbia, SC, 29203
(803) 434-4250
Fax: (803) 434-4277
|
Ongoing Clinical Trials
Amyotrophic Lateral Sclerosis (ALS) and Depression
Researchers at USC School of Medicine are conducting an 8-week study evaluating
the effectiveness of escitalopram (Lexapro®) in the treatment of Major Depression
in ALS. Escitalopram is a FDA approved medication for Major Depressive Disorder.
Read more here...
Schizophrenia/Schizoaffective Disorder with Inadequate Response toTtreatment
Researchers are conducting a 6-month study of long-acting risperidone (Consta)
to see if using higher doses will provide relief of symptoms that have not gone
away with usual doses of antipsychotics.
Read more here...
Schizophrenia/Schizoaffective Disorder and Marijuana Use
Researchers are conducting a 3-month study to study the impact of clozapine on
marijuana use to determine if medication can help people with schizophrenia reduce
marijuana use and improve their mental health.
Read more here...
Schizophrenia/Schizoaffective Disorder and Alcohol Use
Researchers are conducting a 6-month study comparing two types of risperidone
(Risperdal®) to determine if medication can help people with schizophrenia reduce
drinking.
Read more here...
Studies Closed for Accrual:
Autism
Autism is one of the fastest growing developmental disorders that typically
appears during the first three years of life and affects a person’s ability to
communicate and interact with others. Autism is a spectrum disorder affecting
communication and interpersonal skills to varying degrees. Autism affects nearly
1 in every 150 children, has no known cause and is a life-long disorder. Very
few medications are approved to help manage some of the more severe problems
children with autism often experience.
Read more here ...
Bipolar Disorder
Researchers are conducting a study to evaluate the effectiveness of aripiprazole
(Abilify®) when used in combination with either lithium or valproate for the
treatment of mania in Bipolar I Disorder. It is possible for participation to
last up to 58 weeks, including a 4-week Screening/Washout Period, a 2-week Lithium/Valproate
Evaluation Period, a 6-Week Double-Blind Treatment Period and a 46-Week Open-Label
Treatment Period.
Read more here...
Depression
Researchers are conducting a 14-week study of aripiprazole (Abilify®)
to evaluate its safety and effectiveness as an add-on treatment for depression.
Read more here...
Depression
Researchers are conducting a 16-week study of antidepressants and corticotropin
releasing factor (CRF), a chemical which occurs naturally in the body. Researchers
will study what role CRF plays in treating symptoms of depression.
Read more here...
Schizophrenia/Schizoaffective Disorder and Weight Gain
Some people gain weight while taking medications called antipsychotics which
treat the symptoms of schizophrenia. Weight gain can lead to obesity which places
a person at higher risk for diabetes and heart disease. Researchers want to better
understand the issues behind medications for schizophrenia and weight gain.
Read more here...
|
SHOULD YOU PARTICIPATE?
People participate in clinical research for a variety of reasons. People who
volunteer for phase II and phase III trials can gain access to promising drugs
long before these compounds are approved for the marketplace. They typically
will get excellent care from the physicians during the course of the study. This
care also may be free.
Read more here...
HOW TO SIGN UP
If you wish to participate in one of the clinical trials, select the appropriate
trial from those listed to the left and contact the research team member listed
in the Information link at the bottom of the trial description.
|
